Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responses
Edward L Briercheck,Shashidhar Ravishankar,Elshafa Hassan Ahmed,Cesar Camilo Carias Alvarado,Oscar Silva,Elizabeth Solórzano-Ortiz,Marcos Mauricio Siliezar Tala,Philip A Stevenson,Yuexin Xu,Anthony Wilder Wohns,Daniel Enriquez-Vera,Carlos Barrionuevo,Shan-Chi Yu,Aharon G. Freud,Christoph Weigel,Christopher C. Oakes,David M Weinstock,Haley L. Klimaszewski,Apollinaire Ngankeu,Nora Mutalima,Gabriela Samayoa-Reyes,Robert Newton,Rosemary Rochford,Fabiola Valvert,Yasodha Natkunam,Andrei Shustov,Robert A. Baiocchi,Edus H Warren
DOI: https://doi.org/10.1182/bloodadvances.2023012461
IF: 7.642
2024-06-05
Blood Advances
Abstract:Epstein-Barr virus (EBV) is a potent carcinogen linked to hematologic and solid malignancies, causing significant global morbidity and mortality. Therapy using allogeneic EBV-specific lymphocytes shows promise in certain populations, but the impact of EBV genome variation on these strategies remains unexplored. To address this, we sequenced 217 EBV genomes, including hematologic malignancies from Guatemala, Peru, Malawi, and Taiwan, and analyzed them alongside 1,307 publicly available EBV genomes from cancer, non-malignant diseases, and healthy individuals across Africa, Asia, Europe, North America, and South America. These included the first NK/T-cell lymphoma (NKTCL) EBV genomes reported outside East Asia. Our findings indicate that previously proposed EBV genome variants specific to certain cancer types are more closely tied to geographic origin than cancer histology. This included variants previously reported to be specific to NKTCL but were prevalent in EBV genomes from other cancer types and healthy individuals in East Asia. After controlling for geographic region, we did identify multiple NKTCL-specific variants associated with a 7.8- to 21.9- fold increased risk. We also observed frequent variations in EBV genomes affecting peptide sequences previously reported to bind common MHC alleles. Finally, we found several non-synonymous variants spanning the coding sequences of current vaccine targets BALF4, BKRF2, BLLF1, BXLF2, BZLF1, and BZLF2. These results highlight the need to consider geographic variation in EBV genomes when devising strategies for exploiting adaptive immune responses against EBV-related cancers, ensuring greater global effectiveness and equity in prevention and treatment.
hematology